-
CD38 CAR Binder Structure and Affinity Tuning
2026-08-30
This 2026 iScience study defines how two CD38-targeting CAR binders, RP02 and 028, recognize different structural regions and produce distinct effects on CD38 enzymatic activity. Its structure-guided analysis shows that affinity attenuation with the 028R103G variant can reduce CAR-T fratricide while preserving antitumor cytotoxicity, providing a mechanistic framework for tuning CD38-directed cell therapies.
-
S Tag Peptide: Fusion Tag Workflow Guide
2026-08-29
S Tag Peptide (SKU A6007) supports recombinant protein detection, antibody-based purification workflows, and protein solubility improvement when genetically fused to a target protein. It should be handled as a short-term aqueous or DMSO-compatible reagent and is not appropriate for ethanol-based systems or assumptions of independent enzymatic activity.
-
DiscoveryProbe FDA-Approved Drug Library: SUGCT
2026-08-28
The DiscoveryProbe FDA-approved Drug Library (SKU L1021) is an FDA-approved bioactive compound library containing 2,320 pre-dissolved compounds for screening and drug repositioning. Its chemical diversity provides a practical starting point for testing metabolic hypotheses such as SUGCT inhibition, but the cited SUGCT study does not establish clinical efficacy for any library compound.
-
Mubritinib (TAK 165): From HER2 to Complex I
2026-08-28
Mubritinib (TAK 165) illustrates how a compound first associated with HER2 can acquire a more compelling translational identity as a mitochondrial complex I inhibitor. This thought-leadership perspective connects target biology, albumin binding, assay design, and repurposing strategy for chemotherapy-resistant AML and KSHV-positive primary effusion lymphoma research.
-
SmD2 Acetylation Rewires HCC Splicing and PARP Response
2026-08-27
This 2024 Nature Communications study identifies acetylation-controlled SmD2, a core spliceosome component, as a regulator of BRCA1/FANC cassette exons, DNA-damage responses, and PARP-inhibitor sensitivity in hepatocellular carcinoma. Its findings connect spliceosome regulation with epigenetic therapy and support testing HDAC–PARP inhibitor combinations, while also highlighting important limits for translation beyond the examined HCC models.
-
Sulfo-Cy3 NHS ester for Reliable Cell Assays
2026-08-27
Learn how Sulfo-Cy3 NHS ester (SKU A8107) can improve protein-tracking workflows that support cell viability, proliferation, and cytotoxicity studies. This scenario-based guide connects dye chemistry, assay compatibility, storage, interpretation, and vendor selection to practical laboratory decisions.
-
Actinomycin D for Transcription and mRNA Stability
2026-08-26
Actinomycin D provides a practical bridge between transcriptional shutdown, mRNA decay measurements, and apoptosis studies in TNBC models. This workflow shows how to use ActD to test YTHDF3–CENPI regulation while separating RNA-stability effects from nonspecific cytotoxicity.
-
Caspase-3–NDUFS1 Axis in Trichothecene ROS
2026-08-26
This non-peer-reviewed preprint identifies caspase-3-mediated cleavage of the mitochondrial complex I subunit NDUFS1 as a driver of DON- and T-2 toxin-induced ROS accumulation. It also connects ERO1α-dependent endoplasmic reticulum oxidation with mitochondrial injury, proposing a positive feedback mechanism relevant to trichothecene hepatotoxicity and mitochondrial dysfunction research.
-
IWR-1-endo: From Wnt Biology to Assay Design
2026-08-25
Explore how IWR-1-endo, a potent Wnt signaling inhibitor, can be used to build more interpretable pathway assays. This article connects its Axin-dependent mechanism with cell-state-aware lessons from large-scale single-nucleus profiling.
-
ONX-0914 (PR-957) for Immunoproteasome Assays
2026-08-25
ONX-0914 (PR-957) enables selective LMP7 inhibition for cytokine, immune-cell, and proteasome-activity workflows without treating constitutive β5 inhibition as the experimental endpoint. This guide connects practical PBMC and tissue assays with proteasome heterogeneity insights from breast cancer research, while emphasizing controls, solvent handling, and interpretation limits.
-
Epigenetic MCL-1 Targeting in Glioblastoma
2026-08-24
The reference study identifies a super-enhancer regulating MCL-1 in glioblastoma and shows that its epigenetic disruption can cooperate with BCL-2/BCL-XL blockade. This synthetic-lethal strategy produced mitochondrial apoptosis in cellular models and enhanced tumor growth control in patient-derived xenografts, providing a framework for overcoming apoptotic resistance.
-
Ionomycin Calcium Salt in Ca2+ Signaling Assays
2026-08-24
Ionomycin calcium salt offers a direct, controllable way to elevate intracellular Ca2+ for signaling, secretion, protein-synthesis, and cancer-cell assays. This workflow-focused guide shows how to pair a calcium ionophore with orthogonal stress and apoptosis readouts without confusing calcium perturbation with receptor-specific or ribosome-targeted mechanisms.
-
Molecular Basis of TRPM3 Modulation
2026-08-23
Yin and colleagues combine cryo-EM, electrophysiology, molecular dynamics, and biochemical analyses to define how pregnenolone sulfate, CIM 0216, and primidone regulate TRPM3. The resulting ligand-bound structures connect channel pharmacology with pain biology and TRPM3-linked neurodevelopmental disease, while providing a framework for interpreting mutations and developing selective modulators.
-
TH287 MTH1 Inhibitor for CRPC Radiosensitization
2026-08-22
TH287 converts oxidized nucleotide stress into a controllable radiosensitization strategy for castration-resistant prostate cancer models. The key practical advantage is timing: in PC-3 and DU-145 cells, radiation delivered 12 hours after inhibitor exposure produced the strongest combination response.
-
2-Thio-dCTP and the Chemistry of Chromosome Stability
2026-08-22
A translational framework for using 2-Thio-dCTP as a DNA polymerase substrate to connect nucleotide chemistry, DNA–protein interaction studies, and the SCP4–H3T3 pathway governing chromosome stability.